N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease.

[1]  D. Mann.  Recent Insights into the Role of Tumor Necrosis Factor in the Failing Heart , 2001, Heart Failure Reviews.

[2]  L. Wallentin,et al.  A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. , 2002, Journal of the American College of Cardiology.

[3]  TorbjørnOmland,et al.  N-Terminal Pro-B–Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes , 2002 .

[4]  G. Habib,et al.  Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. , 2002, Circulation.

[5]  K. Fox,et al.  Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial , 2002, The Lancet.

[6]  B. Lindahl,et al.  N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. , 2002, Journal of the American College of Cardiology.

[7]  D. Levy,et al.  Impact of age and sex on plasma natriuretic peptide levels in healthy adults. , 2002, The American journal of cardiology.

[8]  L. Wallentin,et al.  The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. , 2002, American heart journal.

[9]  L. Wallentin,et al.  Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). , 2002, The American journal of cardiology.

[10]  Nader Rifai,et al.  Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.

[11]  W. Zoghbi,et al.  Increased Myocardial Gene Expression of Tumor Necrosis Factor-&agr; and Nitric Oxide Synthase-2: A Potential Mechanism for Depressed Myocardial Function in Hibernating Myocardium in Humans , 2002, Circulation.

[12]  M. Entman,et al.  Evidence for an active inflammatory process in the hibernating human myocardium. , 2002, The American journal of pathology.

[13]  D. Morrow,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes☆ , 2002 .

[14]  E. Antman,et al.  Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. , 2002, The American journal of cardiology.

[15]  A. DeMaria,et al.  Utility of B-Natriuretic Peptide in Detecting Diastolic Dysfunction: Comparison With Doppler Velocity Recordings , 2002, Circulation.

[16]  L. Wallentin,et al.  Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. , 2002, Journal of the American College of Cardiology.

[17]  A. Siegbahn,et al.  Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. , 2001, JAMA.

[18]  E. Braunwald,et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. , 2001, The New England journal of medicine.

[19]  R. Doughty,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 2001, Journal of the American College of Cardiology.

[20]  A. Siegbahn,et al.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.

[21]  M. Ohyanagi,et al.  Transient increase in plasma brain (b‐type) natriuretic peptide after percutaneous transluminal coronary angioplasty , 2000, Clinical cardiology.

[22]  M. Kinoshita,et al.  Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? , 1999, Coronary artery disease.

[23]  F. Clubb,et al.  Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.

[24]  D. Gardner,et al.  N ATRIURETIC P EPTIDES , 1998 .

[25]  C. Visser,et al.  C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. , 1997, Circulation.

[26]  T. Takano,et al.  Increased plasma levels of interleukin-6 and myocardial stunning after coronary reperfusion therapy. , 1995, The American journal of cardiology.

[27]  L. Wallentin,et al.  Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease , 1993, Journal of internal medicine.

[28]  R. Simmons,et al.  Interleukin-6 (IL-6) as a mediator of stunned myocardium. , 1993, The American journal of cardiology.

[29]  E. Passamani,et al.  A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. , 1985, The New England journal of medicine.

[30]  Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. , 1984, The New England journal of medicine.